LY 3041658

Drug Profile

LY 3041658

Alternative Names: LY3041658

Latest Information Update: 01 Dec 2016

Price : $50

At a glance

  • Originator Eli Lilly
  • Class Antibodies
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Skin disorders

Most Recent Events

  • 01 Nov 2016 Eli Lilly initiates a phase I trial for Skin disorders in USA (IV) (NCT02896868)
  • 23 Sep 2016 Eli Lilly plans a phase I trial for Skin disorders in USA (IV) (NCT02896868)
  • 30 May 2016 Phase-I development is ongoing in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top